<DOC>
	<DOCNO>NCT00001716</DOCNO>
	<brief_summary>Sickle cell anemia common genetic disease affect African-Americans . About 1 every 1000 African-Americans disease 1 every 12 carry gene could pass child . People sickle cell anemia abnormal hemoglobin , molecules responsible carry oxygen blood . The abnormal hemoglobin cause damage red blood cell . The damage red blood cell may stick blood vessel cause pain injury organ . Some complication cause stick blood cell call acute pain crisis acute chest syndrome ( ACS ) . Nitric oxide ( NO ) gas propose possible therapy ACS complication sickle cell anemia . Studies show NO may favorably affect sickle cell hemoglobin molecule , thereby improve blood flow small vessel . This study design evaluate effect NO , take combination drug call nitroglycerin patient sickle cell anemia normal volunteer . The effect two drug last patient receive . Researchers hope information learn study help develop new therapy sickle cell anemia .</brief_summary>
	<brief_title>Effects Nitric Oxide Nitroglycerin Patients With Sickle Cell Anemia</brief_title>
	<detailed_description>Sickle cell anemia autosomal recessive disorder common genetic disease affect African-Americans . Approximately 0.15 % African-Americans homozygous sickle cell disease , 8 % sickle cell trait . Acute pain crisis acute chest syndrome ( ACS ) common complication sickle cell anemia . Inhaled nitric oxide ( NO ) propose possible therapy ACS . Anecdotally , NO describe rapidly improve hypoxemia clinical course ACS . Furthermore , number recent study suggest NO may favorable impact sickle hemoglobin molecular level could improve abnormal microvascular perfusion characteristic sickle cell anemia . This clinical trial design evaluate physiologic molecular effect inhale NO currently available , safe , FDA-approved medication , nitroglycerin , nitric oxide donor ( i.e. , source NO metabolism body ) , study subject without sickle cell anemia . Whole blood analyze characterize metabolism NO NO donor , molecular interaction hemoglobin NO , duration effect therapy hemoglobin oxygen affinity property erythrocyte intracellular hemoglobin ( include solubility deoxy sickle hemoglobin ) . We also plan characterize effect NO delivery microvascular perfusion study subject without sickle cell anemia . Measurements study subject make prior receive either NO , nitroglycerin , placebo . These perfusion measurement occur rest concentric dorsiflexion exercise . Magnetic resonance imaging ( MRI ) low extremity skeletal muscle enhancement first passage intravenously injected gadolinium contrast use evaluate regional skeletal muscle perfusion . Perfusion measurement pair [ 31 ] Phosphorus Magnetic Resonance Spectroscopy ( [ 31 ] P-MRS ) study concentration muscle high energy phosphate compound . Changes level reflect energy state muscle dependent adequacy blood flow . This study allow three major assessment : firstly , characterization microvascular perfusion rest exercise study subject sickle cell anemia . Secondly , effect NO red cell hemoglobin function skeletal muscle perfusion normal study subject ( without sickle cell anemia ) , finally , effect NO red cell hemoglobin function skeletal muscle perfusion study subject sickle cell anemia . Our hypothesis one effect could potential therapeutic benefit sickle cell anemia patient .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Chest Pain</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>INCLUSION CRITERIA : Males females 18 65 year age . Diagnosis sickle cell disease ( electrophoretic documentation SS homozygosity require ) identification normal volunteer . Hematocrit great 18 % ( absolute reticulocyte count great 100,000/ml ) . Hematocrit 1821 % ( absolute reticulocyte count great 100,000/ml ) : Only 100 ml blood may draw . The study subject may reentered study four week ( repeat full screening lab ) . EXCLUSION CRITERIA : Clinically unstable sickle cell anemia define follow : Having great two acute pain crisis last two month ; hydroxyurea butyrate therapy time last 12 month ; blood transfusion within last three month , % hemoglobin A great 20 % . Age le 18 year great 65 year . Current pregnancy lactation . Inability exercise anterior tibialis muscle . Active cigarette smokerdefined inhalation smoke tobacco product last one month . Medical condition : diabetes mellitus ; coronary artery disease ; peripheral vascular disease ; migraine headache last 12 month ; history previous CVA stroke ; creatinine great 1.0 mg/dL . MRI Exclusions : cardiac pacemaker implantable defibrillator ; aneurysm clip ; neural stimulator ( e.g . TENSUnit ) ; type ear implant ; metal eye ( e.g . machining ) ; implant device ( e.g . insulin pump , drug infusion device ) ; metallic foreign body , shrapnel , bullet . Hematocrit le equal 18 percent : eligible study ; may return evaluation later date . No aspirin nonsteroidal antiinflammatory drug ( NSAIDS caffeine day study . ) Patients opiates acetaminophen exclude . Patients take Viagra exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Hemoglobin</keyword>
	<keyword>P50</keyword>
	<keyword>Microvascular</keyword>
	<keyword>Perfusion</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Sickle Cell Anemia</keyword>
</DOC>